Payment overview · 2025
General Payments
$2,768.08
165 reported records · 29 companies
Healthcare provider profile · identity verified
Charles Vaughan Bulfinch, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · UNION GAP, WA · NPI 1104181221
Verified facts
What the public records show
CMS Open Payments records show Charles Vaughan Bulfinch, D.O. received $2,768.08 in general payments during 2025 across 165 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 49 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 401 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $459.77 | 16.6% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $402.66 | 14.6% | 34 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $274.78 | 9.9% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $244.77 | 8.8% | 18 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $162.62 | 5.9% | 14 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $155.79 | 5.6% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $146.00 | 5.3% | 15 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $114.68 | 4.1% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $110.19 | 4.0% | 7 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $89.25 | 3.2% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $87.53 | 3.2% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $81.00 | 2.9% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $53.57 | 1.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $45.89 | 1.7% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $42.21 | 1.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.35 | 1.4% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $35.42 | 1.3% | 2 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $26.04 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.62 | 0.9% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.12 | 0.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.13 | 0.7% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.09 | 0.7% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $18.03 | 0.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.91 | 0.6% | 1 | 2025 |
| BioWound Solutions, Inc. | Unresolved — no canonical attribution shown | $16.76 | 0.6% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.92 | 0.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.70 | 0.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $13.70 | 0.5% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $13.58 | 0.5% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,768.08 | 165 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $377.31 | 32 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $267.32 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $253.09 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $253.09 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $237.06 | 13 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $227.22 | 23 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $206.84 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $164.66 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $164.66 | 9 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $162.62 | 14 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $155.79 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $150.09 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $114.68 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $110.19 | 7 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $89.25 | 4 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $87.53 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $81.00 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $80.11 | 9 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $54.67 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $53.57 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $52.19 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $45.89 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $42.21 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $39.35 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $36.71 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $35.42 | 2 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $29.33 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $26.04 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.62 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.80 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $23.47 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| MYCAPSSA Normalized: mycapssa |
Drug | Chiesi USA, Inc. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| bio-ConneKt Normalized: bio connekt |
Device | BioWound Solutions, Inc. | $16.76 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| ROTARIX Normalized: rotarix |
Biological | GlaxoSmithKline, LLC. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $13.58 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $6.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 168 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 401 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 203 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 33 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 163 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 37 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 171 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
401 | 102 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
143 | 36 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
203 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
171 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
203 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
95 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
163 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
37 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
168 | 36 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1305 | 336 |
| Lisinopril | Lisinopril | 900 | 241 |
| Omeprazole | Omeprazole | 735 | 182 |
| Levothyroxine Sodium | Levothyroxine Sodium | 697 | 164 |
| Amlodipine Besylate | Amlodipine Besylate | 634 | 160 |
| Losartan Potassium | Losartan Potassium | 599 | 141 |
| Gabapentin | Gabapentin | 559 | 123 |
| Diclofenac Sodium | Diclofenac Sodium | 492 | 123 |
| Trazodone Hcl | Trazodone Hcl | 478 | 107 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 473 | 120 |
| Furosemide | Furosemide | 424 | 107 |
| Farxiga | Dapagliflozin Propanediol | 401 | 102 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 401 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 401 | 94 |
| Duloxetine Hcl | Duloxetine Hcl | 377 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 376 | 92 |
| Montelukast Sodium | Montelukast Sodium | 362 | 77 |
| Metformin Hcl | Metformin Hcl | 358 | 103 |
| Glipizide | Glipizide | 286 | 67 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 283 | 44 |
| Oxycodone Hcl | Oxycodone Hcl | 279 | 48 |
| Tizanidine Hcl | Tizanidine Hcl | 277 | 73 |
| Escitalopram Oxalate | Escitalopram Oxalate | 245 | 55 |
| Pregabalin | Pregabalin | 244 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 241 | 62 |
| Famotidine | Famotidine | 237 | 44 |
| Sertraline Hcl | Sertraline Hcl | 230 | 53 |
| Quetiapine Fumarate | Quetiapine Fumarate | 215 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 209 | 68 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 207 | 46 |
| Simvastatin | Simvastatin | 206 | 46 |
| Jardiance | Empagliflozin | 203 | 43 |
| Topiramate | Topiramate | 203 | 51 |
| Potassium Chloride | Potassium Chloride | 201 | 48 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 200 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 192 | 53 |
| Metformin Hcl Er | Metformin Hcl | 185 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 184 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 175 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 171 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 168 | 47 |
| Eliquis | Apixaban | 168 | 36 |
| Chlorthalidone | Chlorthalidone | 167 | 33 |
| Amitriptyline Hcl | Amitriptyline Hcl | 164 | 34 |
| Ozempic | Semaglutide | 163 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 47 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 159 | 36 |
| Lorazepam | Lorazepam | 156 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 150 | 29 |
| Allopurinol | Allopurinol | 148 | 37 |
| Warfarin Sodium | Warfarin Sodium | 148 | 28 |
| Ezetimibe | Ezetimibe | 146 | 38 |
| Bupropion Hcl Sr | Bupropion Hcl | 144 | 29 |
| Baclofen | Baclofen | 143 | 28 |
| Symbicort | Budesonide/Formoterol Fumarate | 143 | 36 |
| Carvedilol | Carvedilol | 139 | 40 |
| Oxybutynin Chloride | Oxybutynin Chloride | 136 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 43 |
| Tramadol Hcl | Tramadol Hcl | 135 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 130 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 129 | 35 |
| Buspirone Hcl | Buspirone Hcl | 115 | 35 |
| Morphine Sulfate Er | Morphine Sulfate | 110 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 105 | 34 |
| Alprazolam | Alprazolam | 103 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 98 | 30 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 96 | 23 |
| Loperamide | Loperamide Hcl | 95 | 17 |
| Trulicity | Dulaglutide | 95 | 15 |
| Aripiprazole | Aripiprazole | 94 | 20 |
| Lovastatin | Lovastatin | 90 | 24 |
| Meloxicam | Meloxicam | 90 | 21 |
| Ibuprofen | Ibuprofen | 89 | 27 |
| Methocarbamol | Methocarbamol | 87 | 19 |
| Prednisone | Prednisone | 84 | 41 |
| Spironolactone | Spironolactone | 82 | 22 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 79 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 79 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 24 |
| Lamotrigine | Lamotrigine | 75 | 14 |
| Bupropion Xl | Bupropion Hcl | 73 | 14 |
| Atenolol | Atenolol | 72 | 18 |
| Donepezil Hcl | Donepezil Hcl | 70 | 16 |
| Meclizine Hcl | Meclizine Hcl | 70 | 17 |
| Clonazepam | Clonazepam | 67 | suppressed |
| Diazepam | Diazepam | 65 | 13 |
| Estradiol | Estradiol | 65 | 16 |
| Spiriva Respimat | Tiotropium Bromide | 65 | 12 |
| Fenofibrate | Fenofibrate | 61 | 14 |
| Varenicline Tartrate | Varenicline Tartrate | 61 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 59 | 38 |
| Ventolin Hfa | Albuterol Sulfate | 59 | 11 |
| Celecoxib | Celecoxib | 58 | 17 |
| Alendronate Sodium | Alendronate Sodium | 57 | 14 |
| Januvia | Sitagliptin Phosphate | 57 | 12 |
| Ondansetron Odt | Ondansetron | 56 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 54 | 14 |
| Xarelto | Rivaroxaban | 54 | suppressed |
| Glimepiride | Glimepiride | 52 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 52 | 12 |
| Propranolol Hcl | Propranolol Hcl | 52 | 14 |
| Finasteride | Finasteride | 51 | 14 |
| Nabumetone | Nabumetone | 50 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 50 | suppressed |
| Primidone | Primidone | 50 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 14 |
| Synthroid | Levothyroxine Sodium | 49 | 13 |
| Myrbetriq | Mirabegron | 48 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 48 | 15 |
| Acyclovir | Acyclovir | 46 | suppressed |
| Glipizide Er | Glipizide | 46 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 45 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 44 | suppressed |
| Tradjenta | Linagliptin | 44 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 43 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 42 | 15 |
| Prazosin Hcl | Prazosin Hcl | 40 | suppressed |
| Methotrexate | Methotrexate Sodium | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 32 |
| Rybelsus | Semaglutide | 37 | 13 |
| Valacyclovir | Valacyclovir Hcl | 37 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 35 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | suppressed |
| Kerendia | Finerenone | 33 | 11 |
| Lidocaine | Lidocaine | 33 | suppressed |
| Xtampza Er | Oxycodone Myristate | 33 | suppressed |
| Naproxen | Naproxen | 32 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 19 |
| Nystatin | Nystatin | 30 | 15 |
| Bumetanide | Bumetanide | 29 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 22 |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Dulera | Mometasone/Formoterol | 28 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Haloperidol | Haloperidol | 24 | suppressed |
| Lubiprostone | Lubiprostone | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 14 |
| Dapagliflozin | Dapagliflozin Propanediol | 23 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Gemtesa | Vibegron | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 20 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | 13 |
| Methylprednisolone | Methylprednisolone | 19 | 17 |
| Terbinafine Hcl | Terbinafine Hcl | 19 | 15 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Enskyce | Desogestrel-Ethinyl Estradiol | 17 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 14 |
| Humalog | Insulin Lispro | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 12 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Dotti | Estradiol | 14 | suppressed |
| Enbrel Sureclick | Etanercept | 14 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Permethrin | Permethrin | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Falmina | Levonorgestrel/Ethin.Estradiol | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 12 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Calcipotriene | Calcipotriene | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,768.08 · 165 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Auvelity, BEXSERO, BREZTRI, CRENESSITY, ELIQUIS, ENTRESTO, ENTYVIO, FARXIGA, FREESTYLE LIBRE 3, Fibroscan, GEMTESA, INJECTAFER, INSPIRE, ISTURISA, JARDIANCE, Kerendia, Korlym, LEQVIO, LOKELMA, MOUNJARO, MYCAPSSA, NUCALA, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PENMENVY, QULIPTA, Qelbree, RECORLEV, REPATHA, REXULTI, RINVOQ, ROTARIX, Rybelsus, SHINGRIX, SKYRIZI, TRELEGY ELLIPTA, TZIELD, UBRELVY, VOQUEZNA, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND, bio-ConneKt | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error